Introduction
non-vaccinated
CORONAVIRUS, DISEASE, CORONAVIRUS DISEASE 2019, SEVERE ACUTE RESPIRATORY SYNDROME
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a significant concern regarding its global impact on healthcare settingsAfter the viral replication phase, there is an enormous immunological and inflammatory challenge since both innate and adaptive immunity may be disorderly activated by SARS-CoV-2 infectionPropolis is a natural resin produced by bees from various parts of plants. It has several properties, such as antioxidant, anti-inflammatory and immunomodulatory activitiesA recent open-label, randomized clinical trial in adults hospitalized due to COVID-19 has demonstrated the safety and efficacy of Brazilian green propolis (EPP-AF) to decrease length of hospital stay among non-vaccinated patients with moderate to severe symptoms of the disease (including those patients in mechanical ventilation and intensive care therapy) during the first wave of the pandemicAs the pandemic progressed and in light of experimental evidence and properties of propolis, additional clinical trials to gather more evidence are needed. We designed this randomized, double-blind clinical trial to assess safety and impact of EPP-AF on this population during the third wave of the pandemic.